Biohaven (BHVN) Income from Continuing Operations (2021 - 2026)
Biohaven (BHVN) reported Income from Continuing Operations of 130532000.0 for Q1 2026, up 41.12% on a YoY basis from 92499703.23 in Q1 2025, and up 10.32% sequentially from 145555000.0 in Q4 2025.
Biohaven (BHVN) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Biohaven (BHVN) has 6 years of Income from Continuing Operations data on file, last reported at 130532000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 41.12% year-over-year to 130532000.0; the trailing twelve-month figure through Mar 2026 stood at 647677000.0 (up 27.11% YoY), and the FY2025 full-year result was 738822000.0, up 12.71% from the prior year.
- Income from Continuing Operations advanced to 130532000.0 in Q1 2026, from 145555000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 68853000.0 in Q3 2022 to a low of 319771000.0 in Q2 2024.
- A 5-year average of 158483705.88 and a median of 160304000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations plunged 287.59% in 2022 and soared 55.56% in 2023, its largest moves.
- Tracing BHVN's Income from Continuing Operations over 5 years: stood at 201107000.0 in 2022, then gained by 28.02% to 144756000.0 in 2023, then fell by 29.07% to 186843000.0 in 2024, then advanced by 22.1% to 145555000.0 in 2025, then advanced by 10.32% to 130532000.0 in 2026.
- Business Quant data shows BHVN's Income from Continuing Operations at 130532000.0 in Q1 2026, 145555000.0 in Q4 2025, and 173443000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Biohaven | 2.13 Bn | 1.78 Bn | - | -130.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -130.53 Mn |
| Dec 31, 2025 | -145.56 Mn |
| Sep 30, 2025 | -173.44 Mn |
| Jun 30, 2025 | -198.15 Mn |
| Mar 31, 2025 | -221.68 Mn |
| Dec 31, 2024 | -186.84 Mn |
| Sep 30, 2024 | -160.30 Mn |
| Jun 30, 2024 | -319.77 Mn |
| Mar 31, 2024 | -179.50 Mn |
| Dec 31, 2023 | -144.76 Mn |
| Sep 30, 2023 | -102.57 Mn |
| Jun 30, 2023 | -90.35 Mn |
| Mar 31, 2023 | -70.49 Mn |
| Dec 31, 2022 | -201.11 Mn |
| Sep 30, 2022 | -68.85 Mn |
| Jun 30, 2022 | -203.29 Mn |
| Mar 31, 2022 | -97.03 Mn |
| Dec 31, 2021 | -51.89 Mn |
| Sep 30, 2021 | -54.37 Mn |